2 Information about niraparib

2 Information about niraparib

Marketing authorisation indication

Niraparib (Zejula, Tesaro) has a marketing authorisation in the UK for 'the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy'.

Dosage in the marketing authorisation

300 mg, taken orally, once daily until disease progression.


£4,500 for a 56‑capsule pack of 100‑mg capsules; £6,750 for an 84‑capsule pack of 100‑mg capsules (excluding VAT; British national formulary online, accessed March 2018).

The company has a commercial arrangement. This makes niraparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)